MCID: NPH018
MIFTS: 51

Nephrogenic Systemic Fibrosis malady

Categories: Rare diseases, Skin diseases, Nephrological diseases

Aliases & Classifications for Nephrogenic Systemic Fibrosis

About this section
Sources:
48NIH Rare Diseases, 54Orphanet, 68UMLS, 69UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Nephrogenic Systemic Fibrosis:

Name: Nephrogenic Systemic Fibrosis 48 54 68
Nephrogenic Fibrosing Dermopathy 48 54 68
 
Nfd 48
Nsf 48

Classifications:

Orphanet: 54 
Rare skin diseases


External Ids:

Orphanet54 ORPHA137617
UMLS via Orphanet69 C1619692

Summaries for Nephrogenic Systemic Fibrosis

About this section
NIH Rare Diseases:48 Nephrogenic systemic fibrosis is a condition that affects different parts of the body, particularly the skin. Symptoms of the condition may include progressive swelling and tightening of the skin, sometimes resulting in contractures, and pruritis (itching).  The skin findings are similar to those seen in patients with scleroderma.  Nephrogenic systemic fibrosis was first described in 1997. Being exposed to gadolinium-containing contrast agents during MRI testing has been identified as a significant risk factor for development of this disease. Last updated: 4/24/2013

MalaCards based summary: Nephrogenic Systemic Fibrosis, also known as nephrogenic fibrosing dermopathy, is related to neuronal intranuclear inclusion disease and tetanus, and has symptoms including exanthema, pruritus and skin manifestations. An important gene associated with Nephrogenic Systemic Fibrosis is TGFB1 (Transforming Growth Factor Beta 1), and among its related pathways are ALK1 signaling events and Senescence and Autophagy. Affiliated tissues include kidney, skin and eye, and related mouse phenotypes are vision/eye and neoplasm.

Wikipedia:71 Nephrogenic systemic fibrosis (NSF) or nephrogenic fibrosing dermopathy (NFD) is a rare and serious... more...

Related Diseases for Nephrogenic Systemic Fibrosis

About this section

Diseases related to Nephrogenic Systemic Fibrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 65)
idRelated DiseaseScoreTop Affiliating Genes
1neuronal intranuclear inclusion disease11.1
2tetanus11.0
3infant botulism10.8
4congenital fibrosis of the extraocular muscles 1a10.5EDNRA, TGFB1
5head and neck carcinoma10.4SMAD2, SMAD3, TGFB1
6acromesomelic dysplasia10.4SMAD2, SMAD3, SMAD7
7melorheostosis with osteopoikilosis10.4SMAD2, SMAD3, TGFB1
8lymphogranuloma venereum10.4CTGF, TGFB1
9keratopathy10.3SMAD3, TGFB1
10renal dysplasia, bilateral10.3CTGF, SMAD2
11vitreous abscess10.2CTGF, SMAD2, TGFB1
12gallbladder papillomatosis10.2PIK3CA, SMAD4, TGFB1
13vocal cord scarring10.2PIK3CA, SMAD3, SMAD4, SMAD7
14microscopic colitis10.2PIK3CA, SMAD3, SMAD4, SMAD7
15bubonic plague10.2EDN1, EDNRA, TGFB1
16hodgkin's lymphoma, lymphocytic-histiocytic predominance10.1CTGF, EDN1, TGFB1
17iga glomerulonephritis10.1EDN1, EDNRA
18congenital methemoglobinemia10.1SMAD2, TGFB1
19myelitis10.1CCL7, CXCL2, SPP1
20nonspecific interstitial pneumonia10.0CTGF, EDN1, TGFB1
21perrault syndrome10.0CTGF, SMAD2, SMAD3, TGFB1
2246 xy gonadal dysgenesis10.0EDN1, TGFB1, TIMP1
23renal oncocytoma10.0CTGF, SMAD2, SMAD3, TGFB1
24burn scar10.0EDN1, TGFB1, TIMP1
25salt and pepper syndrome10.0CTGF, TGFB1, TIMP1
26echinococcosis10.0CTGF, TGFB1, TIMP1
27liver disease10.0
28granulomatous orchitis10.0CTGF, TGFB1, TIMP1
29paranasal sinus sarcoma10.0CTGF, TGFB1, TIMP1
30hyperekplexia 2, autosomal recessive10.0EDN1, EDNRA
31gingivitis10.0EDN1, TGFB1, TIMP1
32temporomandibular ankylosis9.9CTGF, EDN1, TGFB1
33exudative vitreoretinopathy 19.9CTGF, TGFB1, TIMP1
34twin-to-twin transfusion syndrome9.9DCN, SMAD3, SMAD7, TGFB1
35sarcoma9.9
36benign neonatal seizures9.8CTGF, SMAD2, SMAD3, SMAD7, TGFB1
37lymphedema9.8EDN1, TGFB1, TIMP1
38gemistocytic astrocytoma9.8EDN1, EPO, TGFB1, TIMP1
39actinomycosis9.7CTGF, DCN, SMAD3, TGFB1
40retinitis pigmentosa9.7
41retinitis9.7
42cocaine dependence9.7
43kaposi sarcoma9.7
44atherosclerosis9.7
45hepatitis9.7
46keloids9.7
47spinal cord injury9.7
48lymphoma9.7
49respiratory failure9.7
50pure red-cell aplasia9.7

Graphical network of the top 20 diseases related to Nephrogenic Systemic Fibrosis:



Diseases related to nephrogenic systemic fibrosis

Symptoms & Phenotypes for Nephrogenic Systemic Fibrosis

About this section

UMLS symptoms related to Nephrogenic Systemic Fibrosis:


exanthema, pruritus, skin manifestations, uraemia odour

MGI Mouse Phenotypes related to Nephrogenic Systemic Fibrosis according to GeneCards Suite gene sharing:

41 (show all 20)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053918.1CTGF, DCN, EDNRA, MAPKAP1, PIK3CA, SMAD2
2MP:00020068.1DCN, PIK3CA, SMAD2, SMAD3, SMAD4, SPP1
3MP:00053698.0DCN, EDN1, EDNRA, EPO, PIK3CA, SMAD4
4MP:00053678.0DCN, EDN1, EDNRA, SMAD3, SMAD4, SPP1
5MP:00053807.9CTGF, EDN1, EDNRA, EPO, PIK3CA, SMAD2
6MP:00028737.8CTGF, DCN, EDN1, EDNRA, EPO, SMAD2
7MP:00053897.7DCN, F13A1, PIK3CA, SMAD2, SMAD3, SMAD4
8MP:00053887.6CTGF, DCN, EDNRA, EPO, F13A1, SMAD2
9MP:00053827.4CTGF, DCN, EDN1, EDNRA, SMAD2, SMAD3
10MP:00107717.3CTGF, DCN, EDNRA, EPO, PIK3CA, SMAD2
11MP:00053797.3DCN, EDN1, EDNRA, PIK3CA, SMAD2, SMAD3
12MP:00053817.1CTGF, DCN, EDN1, EDNRA, SMAD2, SMAD3
13MP:00053907.0CTGF, DCN, EDN1, EDNRA, PIK3CA, SMAD2
14MP:00053877.0DCN, EDNRA, EPO, PIK3CA, SMAD2, SMAD3
15MP:00053846.9CTGF, DCN, EDNRA, EPO, MAPKAP1, PIK3CA
16MP:00053976.8DCN, EDNRA, EPO, F13A1, SMAD2, SMAD3
17MP:00053786.3CTGF, DCN, EDN1, EDNRA, PIK3CA, SMAD2
18MP:00053765.6CTGF, DCN, EDN1, EDNRA, EPO, F13A1
19MP:00107685.4CTGF, DCN, EDN1, EDNRA, EPO, F13A1
20MP:00053855.2CTGF, CXCL2, EDN1, EDNRA, EPO, F13A1

Drugs & Therapeutics for Nephrogenic Systemic Fibrosis

About this section

Drugs for Nephrogenic Systemic Fibrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 10)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1Ferrosoferric OxidePhase 4, Phase 3, Phase 164
2Pharmaceutical SolutionsPhase 4, Phase 3, Phase 17793
3Parenteral Nutrition SolutionsPhase 4, Phase 3, Phase 1153
4HematinicsPhase 4, Phase 3, Phase 11630
5Protein Kinase InhibitorsPhase 3, Phase 23612
6Imatinib MesylatePhase 3, Phase 2594123596
7Liver ExtractsPhase 33868
8Plasma-lyte 148Phase 1, Phase 257
9
Iodine5467553-56-2807
Synonyms:
I2
Iode
Iodine-molecule
 
Iodio
Iodum
Jod
Jood
Tincture iodine
10cadexomer iodine514

Interventional clinical trials:

(show all 26)
idNameStatusNCT IDPhase
1Primovist / Eovist in Renally Impaired PatientsCompletedNCT00908596Phase 4
2Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of MagnevistCompletedNCT00744939Phase 4
3Safety of Gadovist in Renally Impaired PatientsCompletedNCT00828737Phase 4
4Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)CompletedNCT00908310Phase 4
5Ferumoxytol Enhanced Magnetic Resonance Angiography in Chronic Kidney DiseaseRecruitingNCT02997046Phase 4
6Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart DiseaseRecruitingNCT02752191Phase 4
7Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF)TerminatedNCT01078987Phase 4
8Nephrogenic Systemic Fibrosis With GadollinumUnknown statusNCT01359345Phase 2, Phase 3
9Treatment of Patients With Nephrogenic Systemic Fibrosis With GlivecCompletedNCT00981942Phase 3
10Efficacy and Safety of Primovist in Chinese PatientsCompletedNCT00526188Phase 3
11Ferumoxytol for Magnetic Resonance Imaging in Patients With Severe Kidney DiseaseRecruitingNCT02954510Phase 3
12Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic FibrosisUnknown statusNCT00677092Phase 2
13The Effect of Crystalloids and Colloids on Visceral Blood FlowCompletedNCT01087853Phase 1, Phase 2
14MRA With Feraheme in HHTRecruitingNCT02977637Phase 1
15Nephrogenic Systemic Fibrosis (NSF): Analysis of Tissue Gadolinium LevelsCompletedNCT01014754
16Validation of a Questionnaire to Identify Signs and Symptoms of Nephrogenic Systemic FibrosisCompletedNCT00869479
17Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MRCompletedNCT01135316
18Evaluation of the Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Without Exposure to Gadolinium Based Contrast Agents (GBCA)CompletedNCT00773409
19Evaluation of the Risk of NSF Following ProHance Injection in Patients With Chronic Kidney DiseaseCompletedNCT00600834
20Evaluation of the Risk of NSF Following MultiHance Injection in Patients With Chronic Kidney DiseaseCompletedNCT00600951
21Magnevist Post-marketing Surveillance in JapanCompletedNCT01376739
22Adverse Reactions to MR and CT-examinations (Enhanced and Unenhanced)CompletedNCT01132339
23Observational Post-marketing Study on the Safety and Efficacy of Dotarem® (SECURE Study)CompletedNCT01523873
24Pilot Study of the Effect of Laser on Reversing Chronic Radiation InjuryRecruitingNCT01910818
25Observational Study on the Incidence of NSF in Renal Impaired Patients Following DOTAREM AdministrationActive, not recruitingNCT01467271
26Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK InjectionSuspendedNCT00811863

Search NIH Clinical Center for Nephrogenic Systemic Fibrosis

Genetic Tests for Nephrogenic Systemic Fibrosis

About this section

Anatomical Context for Nephrogenic Systemic Fibrosis

About this section

MalaCards organs/tissues related to Nephrogenic Systemic Fibrosis:

36
Kidney, Skin, Eye, Liver, Heart, Bone, Endothelial

Publications for Nephrogenic Systemic Fibrosis

About this section

Articles related to Nephrogenic Systemic Fibrosis:

(show top 50)    (show all 414)
idTitleAuthorsYear
1
Nephrogenic systemic fibrosis: a serious adverse reaction to gadolinium - 1997-2006-2016. Part 1. (26802069)
2016
2
Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide. (26885631)
2016
3
Nephrogenic systemic fibrosis: a serious adverse reaction to gadolinium - 1997-2006-2016. Part 2. (26802070)
2016
4
Interaction of Gd-DTPA with phosphate and phosphite: toward the reaction intermediate in nephrogenic systemic fibrosis. (26906409)
2016
5
Nephrogenic systemic fibrosis: fibrotic plaques and contracture following exposure to gadolinium-based contrast media. (27073153)
2016
6
Safety of magnetic resonance contrast media: a review with special focus on nephrogenic systemic fibrosis. (25654421)
2015
7
Half-dose gadoxetic acid-enhanced liver magnetic resonance imaging in patients at risk for nephrogenic systemic fibrosis. (25591579)
2015
8
Nephrogenic systemic fibrosis following gadolinium administration. (26244362)
2015
9
Involvement of the renin-angiotensin system in the development of nephrogenic systemic fibrosis-like lesions in the RenTag mouse model. (26138357)
2015
10
Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol. (26295633)
2015
11
Compensatory biliary and urinary excretion of gadobenate ion after administration of gadobenate dimeglumine (MultiHance(Ar)) in cases of impaired hepatic or renal function: a mechanism that may aid in the prevention of nephrogenic systemic fibrosis? (25651409)
2015
12
Nephrogenic Systemic Fibrosis Risk After Liver Magnetic Resonance Imaging With Gadoxetate Disodium in Patients With Moderate to Severe Renal Impairment: Results of a Prospective, Open-Label, Multicenter Study. (25756684)
2015
13
An Updated Study to Determine Association between Gadolinium-Based Contrast Agents and Nephrogenic Systemic Fibrosis. (26076348)
2015
14
Nephrogenic Systemic Fibrosis on Mammography. (25858556)
2015
15
Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function? (25875973)
2015
16
Evidence Suggesting a Role of Iron in a Mouse Model of Nephrogenic Systemic Fibrosis. (26305890)
2015
17
Nephrogenic Systemic Fibrosis Manifesting a Decade After Exposure to Gadolinium. (26017458)
2015
18
Do ASARM peptides play a role in nephrogenic systemic fibrosis? (26336161)
2015
19
Diagnosis of Nephrogenic Systemic Fibrosis by means of Elemental Bioimaging and Speciation Analysis. (25708271)
2015
20
Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study. (24706993)
2014
21
Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a research on adverse drug events and reports (RADAR) report. (25230161)
2014
22
Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis. (24477507)
2014
23
Perforating osteoma cutis in the setting of longstanding nephrogenic systemic fibrosis. (24962809)
2014
24
Renal function, nephrogenic systemic fibrosis and other adverse reactions associated with gadolinium-based contrast media. (25036056)
2014
25
Nephrogenic systemic fibrosis risk and liver disease. (24778878)
2014
26
The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update. (25257840)
2014
27
Diagnosing nephrogenic systemic fibrosis in the post-FDA restriction era. (24903851)
2014
28
Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents. (24811860)
2014
29
Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the prospective fibrose nephrogAcnique systAcmique study. (24169070)
2014
30
Nephrogenic systemic fibrosis in a gadolinium-naA^ve patient: Successful treatment with oral sirolimus. (25330850)
2014
31
Current status of nephrogenic systemic fibrosis. (24582176)
2014
32
Superior vena cava obstruction associated with nephrogenic systemic fibrosis. (24809889)
2014
33
Role of endothelin-1/endothelin receptor signaling in fibrosis and calcification in nephrogenic systemic fibrosis. (25048859)
2014
34
Substitution of gadolinium ethylenediaminetetraacetate with phosphites: towards gadolinium deposit in nephrogenic systemic fibrosis. (24132302)
2013
35
Nephrogenic systemic fibrosis in denmark- a nationwide investigation. (24349178)
2013
36
The debate between gadolinium versus erythropoietin in a renal transplant patient with nephrogenic systemic fibrosis. (22573525)
2013
37
Evaluation of imatinib mesylate as a possible treatment for nephrogenic systemic fibrosis in a rat model. (22898683)
2013
38
Gadolinium and nephrogenic systemic fibrosis: an update. (24146299)
2013
39
Fibrosis-associated single-nucleotide polymorphisms in TGFB1 and CAV1 are not associated with the development of nephrogenic systemic fibrosis. (23051628)
2013
40
Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. (22865271)
2013
41
Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure. (22977165)
2013
42
Sclerotic bodies beyond nephrogenic systemic fibrosis. (23808625)
2013
43
Nephrogenic systemic fibrosis in a patient with renal failure demonstrating a "reverse superscan" on bone scintigraphy. (23354034)
2013
44
Time-dependent decrement of dermal gadolinium deposits and significant improvement of skin symptoms in a patient with nephrogenic systemic fibrosis after temporary renal failure. (24102613)
2013
45
The treatment of nephrogenic systemic fibrosis with therapeutic plasma exchange. (23426620)
2013
46
A difficult nasogastric tube in a patient with nephrogenic systemic fibrosis. (23857072)
2013
47
Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report. (24057195)
2013
48
Validation of a screening instrument for nephrogenic systemic fibrosis. (23097320)
2013
49
Gadolinium contrast agent-induced CD163+ ferroportin+ osteogenic cells in nephrogenic systemic fibrosis. (23867799)
2013
50
Antifibrotic effect after low-dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis: an open-label non-randomized, uncontrolled clinical trial. (22188390)
2013

Variations for Nephrogenic Systemic Fibrosis

About this section

Expression for genes affiliated with Nephrogenic Systemic Fibrosis

About this section
Search GEO for disease gene expression data for Nephrogenic Systemic Fibrosis.

Pathways for genes affiliated with Nephrogenic Systemic Fibrosis

About this section

Pathways related to Nephrogenic Systemic Fibrosis according to GeneCards Suite gene sharing:

(show all 42)
idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
9.8SMAD4, SMAD7, TGFB1
29.7SMAD3, SMAD4, TGFB1
39.7PIK3CA, SMAD2, SMAD3
49.7SMAD2, SMAD3, SMAD4
5
Show member pathways
9.7SMAD2, SMAD3, SMAD4
69.7SMAD2, SMAD3, SMAD4
79.5PIK3CA, SMAD2, SMAD4, TGFB1
8
Show member pathways
9.5SMAD2, SMAD3, SMAD4, TGFB1
99.5SMAD2, SMAD3, SMAD4, TGFB1
10
Show member pathways
9.5SMAD2, SMAD3, SMAD4, TGFB1
11
Show member pathways
9.5SMAD2, SMAD3, SMAD4, TGFB1
129.5SMAD2, SMAD3, SMAD4, TGFB1
13
Show member pathways
9.5SMAD2, SMAD3, SMAD4, TGFB1
149.5SMAD2, SMAD3, SMAD4, TGFB1
15
Show member pathways
9.5SMAD2, SMAD3, SMAD4, TGFB1
169.5PIK3CA, SMAD2, SMAD3, SMAD4
179.4DCN, SPP1, TGFB1
189.4SMAD2, SMAD3, SMAD4, SMAD7
199.3PIK3CA, SMAD2, SMAD3, SMAD4, TGFB1
20
Show member pathways
9.3PIK3CA, SMAD2, SMAD3, SMAD4, TGFB1
21
Show member pathways
9.3PIK3CA, SMAD2, SMAD3, SMAD4, TGFB1
22
Show member pathways
9.3PIK3CA, SMAD2, SMAD3, SMAD4, TGFB1
239.2SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
24
Show member pathways
9.2SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
259.2SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
269.2SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
27
Show member pathways
9.2SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
289.2EDN1, EPO, SMAD3, SMAD4
299.2DCN, PIK3CA, SMAD2, TGFB1
30
Show member pathways
9.0PIK3CA, SMAD2, SMAD3, SMAD4, SPP1, TGFB1
319.0SMAD2, SMAD3, SMAD4, SMAD7, SPP1, TGFB1
329.0EDN1, EPO, PIK3CA, TIMP1
33
Show member pathways
9.0MAPKAP1, PIK3CA, SMAD2, SMAD3, SMAD4, TGFB1
348.9EDNRA, PIK3CA, SMAD2, SMAD3, SMAD4, TGFB1
358.8EDN1, PIK3CA, SMAD2, SMAD3, SMAD4, TGFB1
368.8CTGF, SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
378.8CTGF, SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
38
Show member pathways
8.0CCL7, CTGF, CXCL2, SMAD3, SMAD4, TGFB1
39
Show member pathways
7.9CCL7, CTGF, EPO, SMAD2, SMAD3, SMAD4
40
Show member pathways
7.8CCL7, CTGF, PIK3CA, SMAD2, SMAD3, SMAD4
41
Show member pathways
7.4CCL7, CXCL2, EDN1, EDNRA, EPO, SMAD3
42
Show member pathways
7.0CCL7, CXCL2, EDN1, EDNRA, MAPKAP1, PIK3CA

GO Terms for genes affiliated with Nephrogenic Systemic Fibrosis

About this section

Cellular components related to Nephrogenic Systemic Fibrosis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1activin responsive factor complexGO:003244410.7SMAD2, SMAD4
2SMAD2-SMAD3 protein complexGO:007114410.5SMAD2, SMAD3
3SMAD protein complexGO:007114110.3SMAD2, SMAD3, SMAD4
4platelet alpha granule lumenGO:003109310.0F13A1, TGFB1, TIMP1
5extracellular matrixGO:00310129.7DCN, TGFB1, TGM2, TIMP1
6transcription factor complexGO:00056679.4SMAD2, SMAD3, SMAD4, SMAD7
7proteinaceous extracellular matrixGO:00055789.3CTGF, DCN, TGFB1, TIMP1
8extracellular spaceGO:00056157.7CCL7, CTGF, CXCL2, DCN, EDN1, EPO
9extracellular regionGO:00055767.4CCL7, CTGF, CXCL2, DCN, EDN1, EPO

Biological processes related to Nephrogenic Systemic Fibrosis according to GeneCards Suite gene sharing:

(show top 50)    (show all 55)
idNameGO IDScoreTop Affiliating Genes
1evasion or tolerance of host defenses by virusGO:001904910.8SMAD3, TGFB1
2pathway-restricted SMAD protein phosphorylationGO:006038910.8SMAD7, TGFB1
3lens fiber cell differentiationGO:007030610.8SMAD3, TGFB1
4common-partner SMAD protein phosphorylationGO:000718210.8SMAD2, TGFB1
5positive regulation of extracellular matrix assemblyGO:190120310.8SMAD3, TGFB1
6positive regulation of SMAD protein import into nucleusGO:006039110.8SMAD4, TGFB1
7activin receptor signaling pathwayGO:003292410.8SMAD2, SMAD3
8embryonic foregut morphogenesisGO:004861710.7SMAD2, SMAD3
9nodal signaling pathwayGO:003809210.7SMAD2, SMAD3
10paraxial mesoderm morphogenesisGO:004834010.7SMAD2, SMAD3
11pericardium developmentGO:006003910.7SMAD2, SMAD3
12regulation of striated muscle tissue developmentGO:001620210.7SMAD3, TGFB1
13response to laminar fluid shear stressGO:003461610.7SMAD7, TGFB1
14response to cholesterolGO:007072310.7SMAD2, TGFB1
15primary miRNA processingGO:003105310.6SMAD2, SMAD3
16regulation of transforming growth factor beta2 productionGO:003290910.6SMAD3, SMAD4
17regulation of epithelial cell proliferationGO:005067810.6EDNRA, SMAD3
18cell activationGO:000177510.6TGFB1, TIMP1
19artery smooth muscle contractionGO:001482410.5EDN1, EDNRA
20histamine secretionGO:000182110.5EDN1, EDNRA
21maternal process involved in parturitionGO:006013710.5EDN1, EDNRA
22neural crest cell developmentGO:001403210.5EDN1, EDNRA
23developmental growthGO:004858910.5SMAD2, SMAD3, SMAD4
24gastrulationGO:000736910.5SMAD2, SMAD3, SMAD4
25positive regulation of inflammatory responseGO:005072910.5CCL7, EDNRA, TGM2
26response to dexamethasoneGO:007154810.4EDN1, EPO
27cellular response to transforming growth factor beta stimulusGO:007156010.4EDN1, SMAD7, TGFB1
28response to transforming growth factor betaGO:007155910.4EDN1, SMAD4
29negative regulation of transforming growth factor beta receptor signaling pathwayGO:003051210.3SMAD2, SMAD3, SMAD7, TGFB1
30positive regulation of odontogenesisGO:004248210.3EDN1, EDNRA, TGFB1
31positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathwayGO:005148210.3EDN1, EDNRA, TGM2
32endoderm developmentGO:000749210.3SMAD2, SMAD3, SMAD4, TGFB1
33response to glucoseGO:000974910.2CTGF, SMAD2, TGFB1
34positive regulation of epithelial to mesenchymal transitionGO:001071810.2SMAD2, SMAD3, SMAD4, TGFB1
35regulation of bindingGO:005109810.2SMAD2, SMAD3, SMAD4, TGFB1
36response to organic substanceGO:001003310.2SPP1, TGFB1, TIMP1
37platelet degranulationGO:000257610.2F13A1, TGFB1, TIMP1
38positive regulation of cell migrationGO:003033510.2CCL7, EDN1, SMAD3, TGFB1
39SMAD protein complex assemblyGO:000718310.1SMAD2, SMAD3, SMAD4, TGFB1
40SMAD protein signal transductionGO:006039510.1SMAD2, SMAD3, SMAD4, TGFB1
41ureteric bud developmentGO:000165710.0SMAD2, SMAD3, SMAD7, TGFB1
42regulation of transforming growth factor beta receptor signaling pathwayGO:00170159.9SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
43extracellular matrix disassemblyGO:00226179.9DCN, SPP1, TIMP1
44positive regulation of ERK1 and ERK2 cascadeGO:00703749.9CCL7, CTGF, EDNRA, EPO
45positive regulation of transcription, DNA-templatedGO:00458939.8EPO, SMAD2, SMAD3, SMAD4, TGFB1
46transforming growth factor beta receptor signaling pathwayGO:00071799.8SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
47intracellular signal transductionGO:00355569.6CTGF, EDN1, SMAD2, SMAD4, SMAD7
48response to hypoxiaGO:00016669.3EDN1, EDNRA, EPO, SMAD3, SMAD4, TGFB1
49negative regulation of transcription from RNA polymerase II promoterGO:00001229.3EDN1, EPO, SMAD2, SMAD3, SMAD4, SMAD7
50positive regulation of cell proliferationGO:00082849.0CTGF, EDN1, EDNRA, EPO, TGFB1, TIMP1

Molecular functions related to Nephrogenic Systemic Fibrosis according to GeneCards Suite gene sharing:

(show all 12)
idNameGO IDScoreTop Affiliating Genes
1co-SMAD bindingGO:007041010.8SMAD2, SMAD3
2enhancer bindingGO:003532610.8SMAD2, SMAD3
3I-SMAD bindingGO:007041110.5SMAD2, SMAD4, SMAD7
4transcription factor activity, protein bindingGO:000098810.4SMAD3, SMAD4
5protein-glutamine gamma-glutamyltransferase activityGO:000381010.4F13A1, TGM2
6transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activityGO:003061810.2SMAD2, SMAD3
7R-SMAD bindingGO:007041210.2SMAD2, SMAD3, SMAD4
8transforming growth factor beta receptor bindingGO:000516010.1SMAD2, SMAD3, TGFB1
9cytokine activityGO:000512510.0EDN1, SPP1, TGFB1, TIMP1
10collagen bindingGO:00055189.9DCN, SMAD3, SMAD4, SMAD7
11type I transforming growth factor beta receptor bindingGO:00347139.8SMAD2, SMAD7, TGFB1
12protein bindingGO:00055154.6CCL7, CTGF, CXCL2, DCN, EDN1, EDNRA

Sources for Nephrogenic Systemic Fibrosis

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet